Alignment Healthcare, Inc. reported an insider sale on March 18, 2026, when Chief Executive Officer John E. Kao sold 73,046 shares of common stock for approximately $1.3 million. The reported sale prices ranged from $17.40 to $18.24 per share.
At the time of the filing, the stock was trading at $18.16 and the company had a market capitalization of $3.76 billion. Analysis included in the filing noted that the company appears undervalued at current levels.
Following the disposal, Mr. Kao retains direct ownership of 1,784,868 shares of Alignment Healthcare. The filing also shows indirect holdings of 2,472,641 shares through the JEK Trust, dated February 8, 2021, for which Mr. Kao serves as trustee.
The filing clarifies the motivation for the sale: shares were sold to meet tax withholding obligations arising from the vesting of restricted stock units. The document specifies that the transaction was not a discretionary sale by Mr. Kao.
Company performance and analyst stance
Alignment Healthcare also disclosed strong fourth-quarter results. The company posted a 25% year-over-year increase in membership and reported revenue growth of 44.4%, a performance that exceeded expectations. In reaction to those results, Raymond James maintained a Strong Buy rating on the stock with a $27.00 price target. Piper Sandler likewise reaffirmed its Overweight rating and set a $30.00 price target following the company’s fourth-quarter 2025 results.
Secondary offering details
In a separate corporate action, an affiliate of General Atlantic, L.P. announced a secondary offering of 13.2 million shares of Alignment Healthcare common stock. Those shares were priced at $19.46 apiece, with the company itself receiving no proceeds from the sale. The transaction is expected to close in March 2026, and J.P. Morgan is serving as the underwriter.
Collectively, the insider sale to cover tax obligations, the refreshed analyst ratings, the company’s reported operating strength, and the pending secondary offering represent a series of concurrent developments that market participants will weigh when assessing Alignment Healthcare’s near-term equity picture.